Results 231 to 240 of about 362,523 (334)

A case of ROS1‐rearranged lung adenocarcinoma in a young man with multiple serosal effusions: Diagnostic pitfalls in pericardial fluid cytology

Precision Medical Sciences, EarlyView.
Abstract ROS1‐rearranged lung adenocarcinoma is a rare subset of non‐small‐cell lung cancer, typically occurring in young never‐smokers. Its occurrence in very young men with a fluid‐dominant presentation is unusual and may lead to diagnostic pitfalls.
Thanh Thao Nguyen, Marie Kawakami, Yoshiiku Okanemasa, Yumi Tsubata, Sohsuke Yamada   +4 more
wiley   +1 more source

Towards Precision Oncology: How Advances in Cancer Genomics, Immunobiology and Artificial Intelligence Will Change Molecular Diagnostics. [PDF]

Biomedicines
Izevbaye I.
europepmc   +1 more source

A new perspective on cancer treatment: the interaction and application prospect between ICIs and radiotherapy

Precision Radiation Oncology, EarlyView.
The combination of immune checkpoint inhibitors (ICIs) and radiotherapy synergistically enhances efficacy through an “antigen release‐immune activation” closed‐loop mechanism, significantly improving outcomes in solid tumors (e.g., lung cancer, melanoma).
Guiling Song, Lei Wang, Guopeng Zhao, Song Tan, Xin Liu, Xinghua Li   +5 more
wiley   +1 more source

Anti-angiogenesis effect of Baiying Juhua Decoction on the non-small cell lung cancer: integrating pharmacology, multi-machine learning and experimental investigation. [PDF]

Bioresour Bioprocess
Meng X, Cao Y, Shen Q, Zhu H, Zhang J, Dong M.   +5 more
europepmc   +1 more source

129TiP: A single arm phase II study evaluating intracranial efficacy of sacituzumab govitecan (SG) with bevacizumab (BEV) in patients (pts) with active, asymptomatic brain metastases (BM) from non-small cell lung cancer (NSCLC) [PDF]

L. Hendriks, Frederike Bensch, Willemijn S.M.E. Theelen, Monique M. Anten, Martijn Broen, L. Jacobi-Postma, Hester Tamminga, Bianca van den Bosch, Sander Croes, Robin M.J.M. van Geel   +9 more
openalex   +1 more source

A sample size analysis of a mathematical model of longitudinal tumor volume and progression‐free survival for Bayesian individual dynamic predictions in recurrent high‐grade glioma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 495-509, March 2025.
Abstract Patients with recurrent high‐grade glioma (rHGG) have a poor prognosis with median progression‐free survival (PFS) of <7 months. Responses to treatment are heterogenous, suggesting a clinical need for prognostic models. Bayesian data analysis can exploit individual patient follow‐up imaging studies to adaptively predict the risk of progression.
Daniel J. Glazar, Solmaz Sahebjam, Hsiang‐Husan M. Yu, Dung‐Tsa Chen, Menal Bhandari, Heiko Enderling   +5 more
wiley   +1 more source

Pharmacological strategies to overcome immune checkpoint inhibitor resistance in non-small cell lung cancer. [PDF]

Front Oncol
Xu Y, Shen H, Shang D, Zhu C.
europepmc   +1 more source

202P: Durvalumab after definitive chemoradiation (dCRT) in non-small cell lung cancer (NSCLC) patients with actionable driver mutations [PDF]

Jol S., K.M. Cheung
openalex   +1 more source

Mechanistic Learning for Predicting Survival Outcomes in Head and Neck Squamous Cell Carcinoma

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 540-550, March 2025.
ABSTRACT We employed a mechanistic learning approach, integrating on‐treatment tumor kinetics (TK) modeling with various machine learning (ML) models to address the challenge of predicting post‐progression survival (PPS)—the duration from the time of documented disease progression to death—and overall survival (OS) in Head and Neck Squamous Cell ...
Kevin Atsou, Anne Auperin, Jôel Guigay, Sébastien Salas, Sebastien Benzekry   +4 more
wiley   +1 more source

Inhibition of GALNT7 suppresses cell proliferation and invasiveness while elevating cell apoptosis via the inactivation of the AKT pathway in non-small cell lung cancer. [PDF]

BMJ Open Respir Res
Zhou Y, Shi Y, Zhou J, Zhu X, Wei Z, Zhang Y.   +5 more
europepmc   +1 more source